MY139403A - Sustained released delivery of amphetamine salts - Google Patents

Sustained released delivery of amphetamine salts

Info

Publication number
MY139403A
MY139403A MYPI20051447A MY139403A MY 139403 A MY139403 A MY 139403A MY PI20051447 A MYPI20051447 A MY PI20051447A MY 139403 A MY139403 A MY 139403A
Authority
MY
Malaysia
Prior art keywords
sustained released
amphetamine salts
released delivery
amphetamine
delivery
Prior art date
Application number
Inventor
Couch Richard
Burnside Beth
Chang Rong-Kun
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Priority to MYPI20051447 priority Critical patent/MY139403A/en
Publication of MY139403A publication Critical patent/MY139403A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A PHARMACEUTICAL COMPOSITION COMPRISES A ONCE-A-DAY SUSTAINED RELEASE FORMULATION OF AT LEAST ONE AMPHETAMINE SALT WHICH PROVIDES MEAN PLASMA CONCENTRATION PROFILE ASPECTS IN HUMAN ADHD PATIENTS WHICH ARE SUBSTANTIALLY THE SAME AS THAT PROVIDED BY ADDERALL XR® TYPE PULSATILE FORMULATIONS.
MYPI20051447 2005-03-31 2005-03-31 Sustained released delivery of amphetamine salts MY139403A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI20051447 MY139403A (en) 2005-03-31 2005-03-31 Sustained released delivery of amphetamine salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20051447 MY139403A (en) 2005-03-31 2005-03-31 Sustained released delivery of amphetamine salts

Publications (1)

Publication Number Publication Date
MY139403A true MY139403A (en) 2009-09-30

Family

ID=45699595

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20051447 MY139403A (en) 2005-03-31 2005-03-31 Sustained released delivery of amphetamine salts

Country Status (1)

Country Link
MY (1) MY139403A (en)

Similar Documents

Publication Publication Date Title
MXPA05003129A (en) Sustained released delivery of amphetamine salts.
CR10327A (en) "PIRIDIN (3-4-b) PIRAZINONAS"
AR068185A1 (en) COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS
IL208982B (en) Composition comprising baclofen, or a salt, or derivative, or sustained release formulation thereof, for use in the treatment of alzheimer's disease
BRPI0509993A (en) combinations comprising alpha-2-delta ligands
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
ATE549016T1 (en) PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION PROFILES FOR POORLY SOLUBLE ACTIVE INGREDIENTS
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
MY143795A (en) Tetrahydropyridoindole derivatives
BRPI0717498A2 (en) COMPOSITIONS, METHODS FOR PREPARING A SURGICAL PREPARATION SOLUTION USED TO DISINFECT A PREOPERATIVE REGION, DISINFECTION METHODS, AND MEDICAL DEVICE.
WO2007093624A3 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
NO20075111L (en) Pharmaceutical composition
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
ZA200708277B (en) Methods,compositions,and formulations for preventing or reducing adverse effects in a patient
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
MX2009012472A (en) Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis.
ECSP066860A (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
IL207928A (en) Pharmaceutical composition comprising a methotrexate (mtx) active agent and a 2,2-anhydropyrimidine adjuvant for reducing mtx toxicity and use thereof in the preparation of medicaments
EP1968606A4 (en) Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
TR200806300A2 (en) Solubility enhancing pharmaceutical formulation
UA92604C2 (en) Stannsoporfin composition having a physiological osmolarity and use thereof
MY139403A (en) Sustained released delivery of amphetamine salts